Venous thromboembolism and cardiopulmonary involvement in Covid 2019 patients: A retrospective observational study

Abstract

Context: The context of the study was venous thromboembolism (VTE) in coronavirus disease 2019 (COVID-19) patients. Aim: The purpose of the study was to understand the prevalence of thrombotic events (pulmonary embolism [PE] and deep-vein thrombosis [DVT]) and right ventricular (RV) dysfunction (RVD) in patients with COVID-19. Settings and Design: Retrospective observational study, Max Hospital, New Delhi, India. Materials and Methods: This study was undertaken in 504 diagnosed COVID-19 adult patients of both genders in the age groups (>40 years and 40 years) during the COVID first and second waves in India. The hospital EMR database of the admitted COVID patients was extracted. Based on the study criteria, the parameters assessed were: D-dimer, CTSS scoring, DVT, RVD, and nature of hospitalization. Statistical Analysis Used: Quantitative variables were expressed in terms of mean and standard deviation. The significance of the association between different variables was evaluated by the Chi-square test. The significance of the difference in age and CTSS score between different categories of PE and DVT was tested by the Student's t-test. Results: The mean age of the patients was 57.13 years. The mean D-dimer level was 502.95 ng/mL. A PE was reported in 101 patients. The severity of the lung involvement as assessed on computed tomography pulmonary angiography was predominant in the bilateral segmental branch (70%), with a mean CTSS score of 14.47, 7.37. DVT was reported in 48 (9.5%) patients. RVD was observed in 14 (2.8%) patients. A significant correlation was found between PE and hospitalization (83.2%, P = 0.003), CTSS (20.07%, P = 0.037, confidence interval 0.10–3.31), and DVT (33.7%, P = 0.001). The prevalence of PE (20.03%) and VTE was 6.7%. RVD was reported in 2.8% of the cases. Conclusion: Our study validates the increased risk of VTE in COVID-19 patients. These findings will be useful to researchers and medical practitioners caring for COVID-19 patients.